Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE: RDY).

If you purchased or otherwise acquired Dr. Reddy’s shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.

You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation focuses on whether Dr. Reddy’s and certain of its officers and/or directors violated federal securities laws. On November 6, 2015, the Company announced that it received a warning letter issued by the U.S. Food & Drug Administration concerning inadequate quality control standards at three of the Company’s manufacturing plants in India. On this news, shares of Dr. Reddy’s fell in value. On August 10, 2017, the Company disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. Following this news, shares of Dr. Reddy’s dropped in value.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.